Table 2 Studies reporting the effects of the CONUT score on outcomes in patients with gastric cancer

Kuroda [7]

37.1 vs 27.7% (P = 0.133)

n.a.

5-year: 77.8 vs 90.6% (P = 0.017)

HR 2.63 (1.16–5.98), P = 0.021**

5-year: 82.3 vs 94.0% (P = 0.019)

HR 4.13 (1.62–10.55), P = 0.003**

5-year: 43.8 vs 84.8% (P < 0.001)

HR 2.72 (1.74–4.25), P < 0.001*

Zheng [8]

n.a.

n.a.

5-year: 51.6 vs 70% (Light vs normal) (P < 0.001)

HR 1.376 (1.005–1.884)*

55.2 vs 70% (Moderate vs normal) (P = 0.017)

HR 1.154 (0.726–1.836), P = 0.137*

n.a.

5-year: 53.2 vs 71.4% (Light vs normal) (P < 0.001)

HR 1.360 (0.984–1.879)*

54.5 vs 71.4% (Moderate vs normal) (P = 0.006)

HR 1.266 (0.753–2.126), P = 0.173*

Liu [9]

26.7 vs 21.9% (P = 0.161)

n.a.

n.a.

5-year: 39.3 vs 55.5% (P < 0.001)

HR 1.553 (1.080–2.232), P = 0.017*

n.a.

Ryo [13]

31.5 vs 26.4%

90-day: 1.4 vs 0.3%

HR 1.33 (0.98–1.81), P = 0.0637**

n.a.

HR 1.74 (1.26–2.41), P = 0.0007*

Suzuki [14]

55.5 vs 36% (P = 0.09)

Infectious: 44.4 vs 25.7% (P = 0.08)

OR 2.36 (0.99–5.40), P = 0.046*

3 vs 0% (P = 0.09)

n.a.

5-year: 64, 75 vs 33% (stage II/III; normal, light vs moderate and severe) (P = 0.003)

HR 3.75 (1.30–10.43), P = 0.015*

5-year: 88, 76 vs 51% (stage I; normal, light vs moderate and severe) (P = 0.044)

64, 53 vs 24% (stage II/III; normal, light vs moderate and severe) (P = 0.007)

HR 2.12 (1.18–3.69), P = 0.012*